Overview

TRIal For Efficacy of Capre on hyperTriglyceridemiA

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for 12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high hypertriglyceridemia as compared to a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Acasti Pharma Inc.
Collaborator:
JSS Medical Research Inc.